Table 1 Baseline characteristics of the control group and patients with epithelial ovarian cancers.
From: Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer
Control group (n = 81 ) | EOC group (n = 91) | p | |||
|---|---|---|---|---|---|
Healthy (n = 24) | Benign (n = 57) | Stage I/II (n = 52) | Stage III/IV (n = 39 ) | ||
Age at enrollment, mean (SD) | 60.7 (52–72) | 59.7 (42–71) | 62.3 (49–77) | 63.6 (54–76) | < 0.05*1 |
Parity | 1.92 (1–3) | 1.84 (1–3) | 1.59 (1–4) | 1.62 (0–3) | < 0.05*3 |
Smoking status | 0.792 | ||||
Yes (%) | 9 (37.5) | 18 (31.6) | 21 (40.4) | 13 (33.3) | |
No (%) | 15 (62.5) | 39 (68.4) | 31 (59.6) | 26 (66.7) | |
BMI | 25.4 (24.2–26.3) | 25.5 (24.1–26.6) | 25.6 (24.7–26.3) | 25.5 (24.1–26.5) | 0.891 |
Menopausal status | 0.842 | ||||
Premenopausal (%) | 10 (41.6) | 24 (42.1) | 18 (34.6) | 14 (35.8) | |
Postmenopausal (%) | 14 (58.4) | 33 (57.9) | 34 (65.4) | 25 (64.2) | |
CRP, mean, (range) (mg/L) | 2.8 (0.8–7.3) | 4.5 (1.2–14) | 14.4(1.6–35) | 20.3 (1.8–54) | < 0.05*3 |
CA125, mean, (range) (U/ml) | 11.5 (3.5–42) | 21.9 (3.4–122) | 126 (7.8–427) | 162.8 (13.6–691) | < 0.05*3 |
HE4, mean, (range) (pmol/L) | 53.2 (5.1–252) | 75.5 (1.5–442) | 147.5 (2–562) | 204.7 (2.61–743) | < 0.05*3 |
